Pharm Tech Minutes 2010.05.27: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
|||
| Line 21: | Line 21: | ||
==Minutes== | ==Minutes== | ||
== | Profile template | ||
==> IHE model profile | |||
=== Profile developments === | |||
Some points may change and may be discussed | |||
Volume 3 will add content from EpSOS and others ressources | |||
Community is XDS/CDA document based, HL7v3 standard based | |||
Hospital is message based. | |||
Cross looking but merge Community and Hospital | |||
Need clarificationon HMW ==> will be discussed at the F2F meeting. | |||
Ex : prescription in active substance vs product brand name | |||
__ where the information come from ? __ | |||
=== CMPD profile developments === | === CMPD profile developments === | ||
=== Logistics for IHE Pharmacy f2f meeting === | === Logistics for IHE Pharmacy f2f meeting === | ||
Revision as of 03:37, 7 June 2010
Agenda
IHE Pharmacy T-Con May 27th 2010
- F2F meeting in Paris : profiles developments
- F2F meeting in Paris : logistics and schedule
Attendees
- Jürgen Brandstaetter, Codewerk, Austria
- Geert Claeys, Agfa Healthcare
- José António Costa Teixeira, Agfa Healthcare
- Thierry Geraud, Carefusion, France
- Isabelle Gibaud, SIB, France
- Simon Letellier, EAHP
- Vassil Peytchev, Epic Systems
- Scott M Robertson, Kaiser Permanente
- Jacqueline Surugue, IHE-Europe Steering Committee, France
- Leonidas Tzimis, EAHP, Greece
Minutes
Profile template ==> IHE model profile
Profile developments
Some points may change and may be discussed
Volume 3 will add content from EpSOS and others ressources
Community is XDS/CDA document based, HL7v3 standard based Hospital is message based.
Cross looking but merge Community and Hospital
Need clarificationon HMW ==> will be discussed at the F2F meeting. Ex : prescription in active substance vs product brand name
__ where the information come from ? __